TrialBreast cancer (Tokyo, Japan)2024

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.

Melinda L Telli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.